ArticleCancer research2016
Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.
Article in Cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 104 citations in OpenAlex.
- Molecular Insights into Pleural Mesothelioma: Unveiling Pathogenic Mechanisms and Therapeutic Opportunities.Diagnostics (Basel, Switzerland) · 2025Review
- Functional Characterization of the Hephaestin Variant D568H Provides Novel Mechanistic Insights on Iron-Dependent Asbestos-Induced Carcinogenesis.International journal of molecular sciences · 2025Article
- Concomitant diagnosis of hypersensitivity pneumonitis and localized epithelioid mesothelioma: a rare case report.Einstein (Sao Paulo, Brazil) · 2025Article
- The genetic susceptibility in the development of malignant pleural mesothelioma: somatic and germline variants, clinicopathological features and implication in practical medical/surgical care: a narrative review.Journal of thoracic disease · 2024Review
- Potential roles of UCH family deubiquitinases in tumorigenesis and chemical inhibitors developed against them.American journal of cancer research · 2024Review
- Exposure to cosmetic talc and mesothelioma.Journal of occupational medicine and toxicology (London, England) · 2023Article
- Diagnostic and Therapeutic Challenges of Malignant Pleural Mesothelioma.Diagnostics (Basel, Switzerland) · 2022Review
- Disease Latency according to Asbestos Exposure Characteristics among Malignant Mesothelioma and Asbestos-Related Lung Cancer Cases in South Korea.International journal of environmental research and public health · 2022Article
- Diagnostics ofDiagnostics (Basel, Switzerland) · 2022Article
- Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP.Targeted oncology · 2022Review
- Understanding exposures and latent disease risk within the National Institute of Environmental Health Sciences Superfund Research Program.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Case report: Mesothelioma and BAP1 tumor predisposition syndrome: Implications for public health.Frontiers in oncology · 2022Article
- Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma.Journal of clinical medicine · 2021Review
- The Evolving Landscape of the Molecular Epidemiology of Malignant Pleural Mesothelioma.Journal of clinical medicine · 2021Review
- Roles and mechanisms of BAP1 deubiquitinase in tumor suppression.Cell death and differentiation · 2021Review
- Malignant pleural mesothelioma: an update.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2021Review
- Polycomb group-mediated histone H2A monoubiquitination in epigenome regulation and nuclear processes.Nature communications · 2020Review
- BAP1: Not just a BRCA1-associated protein.Cancer treatment reviews · 2020Review
- Biological Mechanisms and Clinical Significance ofCancer discovery · 2020Review
- Inherited Genetic Mutations and Polymorphisms in Malignant Mesothelioma: A Comprehensive Review.International journal of molecular sciences · 2020Review
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Heritable mutations in the BAP1 tumor suppressor gene predispose individuals to mesothelioma and other cancers. However, a large-scale assessment of germline BAP1 mutation incidence and associated clinical features in mesothelioma patients with a family history of cancer has not been reported. Therefore, we examined the germline BAP1 mutation status of 150 mesothelioma patients with a family history of cancer, 50 asbestos-exposed control individuals with a family history of cancers other than mesothelioma, and 153 asbestos-exposed individuals without familial cancer. No BAP1 alterations were found in control cohorts, but were identified in nine of 150 mesothelioma cases (6%) with a family history of cancer. Alterations among these cases were characterized by both missense and frameshift mutations, and enzymatic activity of BAP1 missense mutants was decreased compared with wild-type BAP1. Furthermore, BAP1 mutation carriers developed mesothelioma at an earlier age that was more often peritoneal than pleural (five of nine) and exhibited improved long-term survival compared to mesothelioma patients without BAP1 mutations. Moreover, many tumors harboring BAP1 germline mutations were associated with BAP1 syndrome, including mesothelioma and ocular/cutaneous melanomas, as well as renal, breast, lung, gastric, and basal cell carcinomas. Collectively, these findings suggest that mesothelioma patients presenting with a family history of cancer should be considered for BAP1 genetic testing to identify those individuals who might benefit from further screening and routine monitoring for the purpose of early detection and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.